Terug naar bedrijfspagina

Nieuws over Hyloris Pharmaceuticals

05/04/2024 2024 04 Een goed 2024 tegemoet

14/03/2024 HYLORIS - Reports Full Year Results for 2023 & Provides Business Outlook - Communication at the request of the FSMA on the transactions with Qliniq (14.03.2024)

27/02/2024 Hyloris - Announces Launch of Maxigesic® IV in the U.S. and approval In Canada (27.02.2024)

14/02/2024 Hyloris - Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures (14.02.2024)

30/01/2024 Hyloris - and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) (30.01.2024)

30/01/2024 Hyloris - en Purna Female Healthcare kondigen positieve resultaten aan van Fase 2 studie bij patiënten met acute vulvovaginale candidiasis (VVC) (30.01.2024)

18/01/2024 Hyloris - verbreedt pijplijn met nieuw kandidaat-product voor Vulva Lichen Sclerosus (VLS) (18.01.2024)

16/01/2024 Hyloris - Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) (16.01.2024)

26/12/2023 Hyloris kondigt positieve klinische studieresultaten aan voor Valacyclovir orale suspensie (HY-029) (26.12.2023)

21/12/2023 Hyloris - verbreedt pijplijn met nieuw kandidaat-product voor het Burning Mouth Syndrome (21.12.2023)

04/12/2023 Hyloris - announces US FDA approval for Podofilox Gel (04.12.2023)

07/11/2023 ‘Er zit nog genoeg goed nieuws aan te komen’

24/10/2023 Hyloris - Announces Out-Licensing of Atomoxetine Oral Liquid in Canada (24.10.2023)

18/10/2023 Hyloris - announces U.S. FDA Approval of Maxigesic® IV (18.10.2023)

03/10/2023 2023 08 - Goed opweg naar hogere sferen

07/09/2023 Hyloris Pharmaceuticals - Reports 2023 Half-Year Results and provides Business Outlook (07.09.2023)

23/06/2023 Hyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura (22.06.2023)

08/06/2023 Hyloris - has been granted EUR 1 million in non-dilutive funding from the Walloon Region (08.06.2023)

02/05/2023 Hyloris - announces potential registration date for Maxigesic® IV in the US (02.05.2023)

18/04/2023 Hyloris - announces submission of Maxigesic® IV packaging data requested by the US FDA (18.04.2023)

19/09/2023 2023 04 - Goed op weg naar hogere sferen

15/03/2023 Hyloris - reports full year results for 2022 & provides business outlook (15.03.2023)

07/02/2023 Interview met Stijn Van Rompay, ceo en oprichter van Hyloris

24/01/2023 Hyloris - announces commercial partnership for Maxigesic® IV in 9 European countries (24.01.2023)

20/01/2023 Hyloris Pharmaceuticals - expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood (hypophosphatemia) (20.01.2023)

23/11/2022 Hyloris Pharmaceuticals - Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis (23.11.2022)

22/11/2022 Hyloris Pharmaceuticals - Broadens Pipeline with a Proprietary Intranasal Product Candidate of a TRPV11 agonist (HY-083) for Idiopathic Rhinitis (22.11.2022)

03/10/2022 2022 08 - Timmert verder aan de weg

01/09/2022 Hyloris Pharmaceuticals - Reports 2022 Half-Year Results and Provides Corporate Update (01.09.2022)

20/07/2022 Hyloris - Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures (20.07.2022)

01/07/2022 HYLORIS - US FDA seeks more information on Maxigesic IV application (01.07.2022)

01/04/2022 Hyloris - Successfully Raises EUR 15.0 Million in an Equity Offering by Means of A Private Placement Via an Accelerated Bookbuild Offering (01.04.2022)

05/04/2022 2022 04 - De eerste tastbare omzet is binnen

16/03/2022 Hyloris - reports results for the full year 2021 (16.03.2022)

17/12/2021 Hyloris - gaat strategisch partnerschap aan met Vaneltix voor de behandeling van acute pijn bij interstitiële cystitis (17.12.2021)

15/11/2021 Hyloris - kondigt eerder dan verwachte PDUFA-datum aan voor Maxgesic® IV (15.11.2021)

10/11/2021 Hyloris - Broadens Pipeline with Novel Patented Combination Product Candidate in Acute Myeloid Leukaemia and Small Cell Lung Cancer (10.11.2021)

02/11/2021 Hyloris - kondigt start aan van fase 2-onderzoek van miconazol-domiphenbromide vaginale crème bij vulvovaginale candidiasis (02.11.2021)

01/11/2021 Hyloris - Announces FDA Acceptance of New Drug Application for Maxigesic® IV in Post-Operative Pain (01.11.2021)

19/10/2021 Hyloris Announces Approval of Maxigesic® IV in the UK and Ireland (19.10.2021)

13/10/2021 Hyloris - Acquires Breakthrough, Patented Technology to Develop and Market Aspirin IV in the U.S. in Acute Coronary Syndrome (13.10.2021)

21/09/2021 Hyloris - Announces Further Extension of Maxigesic® IV Footprint (21.09.2021)

06/09/2021 2021 07 - Interview met Stijn Van Rompay

04/08/2021 Hyloris - Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead (3.8.2021)

08/07/2021 Hyloris - Announces Launch of Maxigesic® IV, a Novel Non-Opioid Pain Treatment, in Key European Markets (08.07.2021)

24/06/2021 Hyloris - Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group (24.06.2021)

28/04/2021 Hyloris - Announces Major Commercial Partnership in the U.S. for Maxigesic IV (28.04.2021)

08/04/2021 Hyloris - Announces Further Extension of European Footprint of Maxigesic® IV (08.04.2021)

26/04/2021 2021 04 - Uitkijken naar meer inkomsten

09/03/2021 Hyloris - Press-Release-FY20_ENG (09.03.2021)

05/03/2021 Hyloris’ - Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets (05.03.2021)

07/02/2021 Hyloris voegt eerste project aan de pijplijn toe

05/02/2021 Hyloris - Hyloris & Purna Female Healthcare announce partnership (05.02.2021)

13/10/2020 2020 08 - Fast lane in de farmasector

29/06/2020 “Onze markt biedt enorme kansen” Interview met Hyloris topman Stijn Van Rompay

22/06/2020 2020 06 - Interview Stijn Van Rompay - Hyloris Pharmaceuticals

19/06/2020 Retail road show presentatie Hyloris Pharmaceuticals